



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

[vaincrelamuco.org](http://vaincrelamuco.org)

[federation-crcm.org](http://federation-crcm.org)



# L'entraînement sportif des jeunes atteint de mucoviscidose : jusqu'où peut-on aller ?

Vincent DANIEL

Médecine du sport – EFR

CHU Rennes





LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les recommandations

### Activité physique régulière

- Pour les enfants de moins de 5 ans, au moins **3 h/j d'AP** sont recommandées soit 15 min/h pour 12h d'éveil.
- Pour les enfants et adolescents âgés de 6 à 17 ans, au moins **60 min/j d'AP** d'intensité modérée à élevée sont recommandées.

### Limiter la sédentarité

- limiter la durée quotidienne totale des activités sédentaires en période d'éveil,
- limiter la durée de chaque activité sédentaire, pour **ne pas dépasser 1h en continu pour les moins de 5 ans et 2h pour les 6-17 ans.**





**LYON**  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

**3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE**

vaincrelamuco.org

federation-crcm.org



**Aerobic training compared with no physical training for cystic fibrosis**

**Patient or population:** adults and children with cystic fibrosis

**Settings:** Outpatients

**Intervention:** Aerobic training

**Comparison:** No physical training

| Outcomes   | Illustrative comparative risks* (95% CI)   |                    | Relative effect (95% CI) | No of participants (studies)             | Quality of the evidence (GRADE) | Comments |
|--|--|--------------------|--------------------------|--|---------------------------------|----------|
|  | Assumed risk   | Corresponding risk |                          |  |                                 |          |
|  | No physical training   | Aerobic training   |                          |  |                                 |          |
| <p><b>Exercise capacity:</b> change in VO<sub>2</sub> peak during maximal exercise (mL/min per kg body weight)</p> <p>Follow-up: from hospital discharge up to 3 years</p> | Short-term improvements in exercise tolerance during aerobic training were significantly greater than with no physical training at hospital discharge and 1 month after hospital discharge | NA                 | 170 (4 studies)          | ⊕○○○<br><b>very low</b> <sup>1,2,3</sup> |                                 |          |
| <p><b>Pulmonary function:</b> change in FEV<sub>1</sub> (% predicted)</p> <p>Follow-up: from hospital discharge up to 3 years</p>  | There were no short-term differences between groups at hospital discharge or one month after hospital discharge  | NA                 | 187 (5 studies)          | ⊕⊕○○<br><b>low</b> <sup>1,2</sup>        |                                 |          |

Cochrane Database Syst Rev. 2017 Nov 1;11:CD002768. Physical exercise training for cystic fibrosis. Radtke T, Nevitt SJ, Hebestreit H, Kriemler S.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

# 3<sup>ES</sup> JOURNÉES FRANCOPHONES DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



|  |   |    |                    |                                      |
|--|---|----|--------------------|--------------------------------------|
|  | ferences in annual change of pulmonary function between groups were observed over 36 months   |    |                    |                                      |
| <b>HRQoL</b><br>CFQ Quality of Well-being Scale and perceived 'positive effects.'<br>Follow-up: one month after hospital discharge up to three years | No significant differences between the groups were shown according to the CFQ. A significant improvement in HRQoL according to the Quality of Well-being Scale was observed in the aerobic exercise group compared to the no physical training group at 1 month after hospital discharge, MD 0.10 (95% CI 0.03 to 0.17).<br>Positive effects were reported by 43 out of 49 participants (not reported by treatment group) | NA | 143<br>(3 studies) | ⊕⊕○○<br><b>low</b> <sup>1,4</sup>    |
| <b>CF-related mortality</b><br>Follow-up: NA   | Outcome not reported.   |    |                    | NA                                   |
| <b>Pulmonary exacerbations:</b> number of hospitalisations and number of days in hospital<br>Follow-up: up to three years                            | There were no between-group differences reported for the mean number of hospitalisations or mean number of days in hospital at year 1, 2 and 3  | NA | 65<br>(1 study)    | ⊕⊕○○<br><b>low</b> <sup>1,5</sup>    |
| <b>Diabetic control</b><br>Follow-up: NA   | Outcome not reported.   |    |                    | NA                                   |
| <b>Adverse events</b><br>Follow-up: up to two years  | One study reported that no adverse effects occurred. In the other study, 1 participant in the aerobic training group injured her ankle and missed 2 days of aerobic training. One participant from the control group developed haemoptysis and withdrew from the study  | NA | 71<br>(2 studies)  | ⊕⊕⊕○<br><b>moderate</b> <sup>1</sup> |

Cochrane Database Syst Rev. 2017 Nov 1;11:CD002768. Physical exercise training for cystic fibrosis. Radtke J, Nevitt SJ, Hebestreit H, Kriemler S.



**LYON**  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

**3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE**

vaincrelamuco.org

federation-crcm.org



**Anaerobic training compared with no physical training for cystic fibrosis**

**Patient or population:** adults and children with cystic fibrosis

**Settings:** outpatients

**Intervention:** anaerobic training

**Comparison:** no physical training

| Outcomes   | Illustrative comparative risks* (95% CI)  |                    | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments |
|--|---|--------------------|--------------------------|------------------------------|---------------------------------|----------|
|  | Assumed risk  | Corresponding risk |                          |                              |                                 |          |
|  | No physical training  | Anaerobic training |                          |                              |                                 |          |
| <p><b>Exercise capacity:</b> change in VO<sub>2</sub> peak during maximal exercise (mL/min per kg BW)<br/>Follow-up: from hospital discharge up to 3 years</p> | One study showed a significant improvement in exercise capacity following anaerobic training at 6 months compared to no physical training<br>No significant differences between groups were observed at any other time points   | NA                 | 86 (3 studies)           | ⊕⊕○○<br>low <sup>1,2</sup>   |                                 |          |
| <p><b>Pulmonary function:</b> change in FEV<sub>1</sub> (% predicted)<br/>Follow-up: from hospital discharge up to 3 years</p>                                 | Two studies showed a significant improvement in pulmonary function during and following anaerobic training at hospital discharge, 1 month after discharge, 3 months, 6 months and 18 months post-training compared to no physical training<br>The second study showed no significant differences in lung function at any time point | NA                 | 86 (3 studies)           | ⊕⊕○○<br>low <sup>1,2</sup>   |                                 |          |

Cochrane Database Syst Rev. 2017 Nov 1;11:CD002768. Physical exercise training for cystic fibrosis. Radtke T, Nevitt SJ, Hebestreit H, Kriemler S.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



|   |   |    |                   |                               |
|---|---|----|-------------------|-------------------------------|
| <b>HRQoL</b> , Quality of Well-being Scale or HRQoL scale physical function<br>Follow-up: up to 2 years | No significant differences between groups were observed according to the Quality of Well-being Scale or HRQoL scale physical function | NA | 64<br>(2 studies) | ⊕⊕○○<br>low <sup>1,3</sup>    |
| <b>CF-related mortality</b><br>Follow-up: NA  | Outcome not reported.   |    |                   | NA                            |
| <b>Pulmonary exacerbations</b><br>Follow-up: NA   | Outcome not reported.   |    |                   | NA                            |
| <b>Diabetic control</b><br>Follow-up: NA  | Outcome not reported.   |    |                   | NA                            |
| <b>Adverse events</b><br>Follow-up: 2 years   | One study reported that no adverse effects occurred.  | NA | 22<br>(1 study)   | ⊕⊕⊕○<br>moderate <sup>1</sup> |

\* The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; HRQoL: health-related quality of life; NA: not applicable; VO<sub>2 peak</sub>: peak oxygen consumption.

GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

1. Downgraded once due to risk of bias: methodological details of the studies relating to randomisation and allocation concealment were unclear; one study used an inadequate method of randomisation and allocation concealment which may have introduced bias.
2. Downgraded once due to applicability: the no physical training group of one study deteriorated more than expected, this should be taken into account when interpreting results.
3. Downgraded once due to applicability: unclear if the measures and questionnaires used were validated in this population.



**LYON**  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

**3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE**

vaincrelamuco.org

federation-crcm.org



**Combined aerobic and anaerobic training compared with no physical training for cystic fibrosis**

**Patient or population:** adults and children with cystic fibrosis

**Settings:** outpatients

**Intervention:** combined aerobic and anaerobic training

**Comparison:** no physical training

| Outcomes  | Illustrative comparative risks* (95% CI)  |   | Relative effect (95% CI) | No of participants (studies)      | Quality of the evidence (GRADE)  | Comments |
|---|---|---|--------------------------|-----------------------------------|--|----------|
|   | Assumed risk  | Corresponding risk                      |                          |                                   |  |          |
|   | No physical training  | Combined aerobic and anaerobic training |                          |                                   |  |          |
| <b>Exercise capacity:</b> change in $\dot{V}O_2$ peak during maximal exercise (mL/min per kg body weight)<br>Follow-up: 12 weeks to two years | A significantly higher $\dot{V}O_2$ peak was found in the combined training compared to the no physical training group after 12 to 18 months in 1 study<br>No significant difference between groups was found at any other time point | NA                                      | 52 (2 studies)           | ⊕⊕○○<br><b>low</b> <sup>1,2</sup> | Two additional studies recruiting 42 participants showed significant group x time interactions for $\dot{V}O_2$ peak; however, these results are not included in this review due to concerns over inconsistencies in the data provided to us by the original trial authors |          |
| <b>Pulmonary function:</b> change in FEV <sub>1</sub> (% predicted) or mL<br>Follow-up: 12 weeks to two years                                 | No significant differences in pulmonary function were observed between treatment groups at any time point   | NA                                      | 103 (3 studies)          | ⊕⊕○○<br><b>low</b> <sup>1,2</sup> |  |          |

Cochrane Database Syst Rev. 2017 Nov 1;11:CD002768. Physical exercise training for cystic fibrosis. Radtke J, Nevitt SJ, Hebestreit H, Kriemler S.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



|   |   |    |                   |                                   |  |
|---|---|----|-------------------|-----------------------------------|--|
| <b>HRQoL:</b> CFQ, Medical Outcomes Study-36 Item Short-Form Health Survey, SF-36<br>Follow-up: 12 weeks to 2 years | Two studies showed no significant differences in any HRQoL scale<br>One study showed a significant improvement in subjective health perception in the combined training group after 3 to 6 months and after 12 to 18 months (but not between 6 and 12 months) | NA | 93<br>(3 studies) | ⊕○○○<br>very low <sup>1,2,3</sup> |  |
| <b>CF-related mortality</b><br>Follow-up: NA  | Outcome not reported.   |    |                   |                                   | NA   |
| <b>Pulmonary exacerbations</b><br>Follow-up: NA   | Outcome not reported.   |    |                   |                                   | NA   |
| <b>Diabetic control</b><br>Follow-up: 12 weeks  | Significant differences in some of the parameters were observed in the no physical training group compared to the combined training group and vice versa<br>Also no significant differences were observed for some parameters                                 | NA | 14<br>(1 study)   | ⊕○○○<br>very low <sup>1,2,3</sup> | The study reported a range of metabolic parameters (HbA1c(%), Glucose AUC, Total Insulin AUC, Insulin Sensitivity Index) Plasma Glucose and Plasma Insulin |
| <b>Adverse events</b><br>Follow-up: NA  | Outcome not reported.   |    |                   |                                   | NA   |

\* The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**AUC:** area under the curve; **CFQ:** Cystic Fibrosis Questionnaire; **CI:** confidence interval; **FEV<sub>1</sub>:** forced expiratory volume in 1 second; **HRQoL:** health-related quality of life; **NA:** not applicable; **VO<sub>2</sub> peak:** peak oxygen consumption.

GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

[Cochrane Database Syst Rev.](#)  
2017 Nov 1;11:CD002768. **Physical exercise training for cystic fibrosis.**  
[Radtke J,](#)  
[Nevitt SJ,](#)  
[Hebestreit H,](#)  
[Kriemler S.](#)





LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Evaluation de la condition physique et mucoviscidose

### TM6'

- Peu corrélé au  $VO_2$  max chez l'enfant

### Step test

- Step de 15cm, 30/min et 3 min
- Souvent sous max et non progressif

### Test navette

- 20m, départ 4 km/h et  $\uparrow$  0.5 km/h/min
  - Validé pour CF
- 10m
  - Validé pour CF adulte

[Statement on Exercise Testing in Cystic Fibrosis](#). Hebestreit H, Arets HG, Aurora P, Boas S, Cerny F, Hulzebos EH, Karila C, Lands LC, Lowman JD, Swisher A, Urquhart DS; European Cystic Fibrosis Exercise Working Group. Respiration. 2015;90(4):332-51.

[Validation of shuttle tests in children with cystic fibrosis](#). Selvadurai HC, Cooper PJ, Meyers N, Blimkie CJ, Smith L, Mellis CM, Van Asperen PP. Pediatr Pulmonol. 2003 Feb;35(2):133-8.

[Validity of a modified shuttle test in adult cystic fibrosis](#). Bradley J, Howard J, Wallace E, Elborn S. Thorax. 1999 May;54(5):437-9.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE


vaincrelamuco.org

federation-crcm.org



## Evaluation de la condition physique et mucoviscidose

- Évaluation par l'EFX (max)
  - Extrapolation moins fiable
  - Tapis, ergocycle...
  - $VO_2$ max corrélée :
    - Mortalité
    - QoL
    - Hospitalisation



**Figure 1. Schematic of the exercise test protocol.** A: 3-min warm up at 20 W. B: Incremental ramp exercise at a rate of 10–30 W/min (individualized to patients' anthropometric data). C: 5-min active recovery (unloaded pedaling). D: 10-min seated recovery off the cycle ergometer. E: 3-min warm-up at 20 W. F: Supramaximal confirmation bout of exercise to volitional exhaustion at 110% of the peak power output produced in the prior ramp exercise test B. G: 3-min recovery (unloaded pedaling).

[N Engl J Med.](#) 1992 Dec 17;327(25):1785-8. The prognostic value of exercise testing in patients with cystic fibrosis. [Nixon PA](#)<sup>1</sup>, [Orenstein DM](#), [Kelsey SF](#), [Doershuk CF](#).

[Pediatr Pulmonol.](#) 2018 Jan;53(1):36-42. The oxygen uptake efficiency slope is not a valid surrogate of aerobic fitness in cystic fibrosis. [Williams CA](#)<sup>1,2</sup>, [Tomlinson OW](#)<sup>1,2</sup>, [Chubbock LV](#)<sup>1</sup>, [Stevens D](#)<sup>3</sup>, [Saynor ZL](#)<sup>4</sup>, [Oades PJ](#)<sup>2</sup>, [Barker AR](#)<sup>1</sup>.

[Statement on Exercise Testing in Cystic Fibrosis.](#) Hebestreit H, Arets HG, Aurora P, Boas S, Cerny F, Hulzebos EH, Karila C, Lands LC, Lowman JD, Swisher A, Urquhart DS; European Cystic Fibrosis Exercise Working Group. *Respiration.* 2015;90(4):332-51.

[Cystic fibrosis and physiological responses to exercise.](#) Williams CA, Saynor ZL, Tomlinson OW, Barker AR. *Expert Rev Respir Med.* 2014 Dec;8(6):751-62.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE


vaincrelamuco.org

federation-crcm.org



## Réponses à l'exercice physique et mucoviscidose

- Facteur limitant l'exercice
  - Métabolisme énergétique musculaire /↓ capacité oxydative
  - ↓ performances anaérobies
    - Sprint, Wingate
  - Mortalité corrélée masse musculaire
  - Recommandations d'exercices de renforcement musculaire



[Cystic fibrosis and physiological responses to exercise.](#)

Williams CA, Saynor ZL, Tomlinson OW, Barker AR. Expert Rev Respir Med. 2014 Dec;8(6):751-62.

[J Cyst Fibros.](#) 2017 Sep;16(5):538-552. **Peripheral muscle abnormalities in cystic fibrosis: Etiology, clinical implications and response to therapeutic interventions.** [Gruet M<sup>1</sup>](#), [Troosters T<sup>2</sup>](#), [Verges S<sup>3</sup>](#).

Fogarty AW, Britton J, Clayton A, Smyth AR. Are measures of body habitus associated with mortality in cystic fibrosis? Chest 2012;142:712-7.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE


vaincrelamuco.org

federation-crcm.org




## Protocoles d'entraînement

Classique



Aérobie

- Marche, vélo, vélo elliptique
- Début à 60% VO<sub>2</sub>pic
- Semaines 5-8 : 70%VO<sub>2</sub>pic
- Semaines 9-12 : 80%VO<sub>2</sub>pic



Renforcement musculaire

- 5-7 exercices des principaux groupes musculaires
- Poids du corps, poids libres ou élastiques
- Objectif : 8-12 répétitions à 30-50% FMV
- Augmentation progressive de l'intensité et de la fréquence

...



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Exercices de haute intensité

Baseline patient characteristics.

| Variable                              |                          |
|---------------------------------------|--------------------------|
| N                                     | 33                       |
| Sex (M/F)                             | 17/16                    |
| Age (y)                               | 19 (9) (9–43)            |
| Height (cm)                           | 159 (14) (131–187)       |
| Weight (kg)                           | 54.2 (15.0) (25.8–77.1)  |
| BMI (kg/m <sup>2</sup> )              | 20.6 (3.5) (14.6–26.6)   |
| Body fat (%)                          | 25.9 (7.8) (12.0–40.8)   |
| FEV <sub>1</sub> (% predicted)        | 80.8 (18.6) (45.0–111.0) |
| CRP (mg/L)                            | 3.11 (5.70) (0.10–26.74) |
| Systolic blood pressure (mm Hg)       | 107 (11) (89–143)        |
| Diastolic blood pressure (mm Hg)      | 62 (7) (43–79)           |
| Resting O <sub>2</sub> saturation (%) | 97.6 (1.5) (94.0–100.0)  |
| <i>Maximal Exercise Test</i>          |                          |
| VO <sub>2</sub> peak (L/min)          | 1.60 (0.59) (0.69–2.90)  |
| VO <sub>2</sub> peak (mL/kg/min)      | 30.2 (5.9) (17.1–40.6)   |
| VO <sub>2</sub> peak (mL/kgFFM/min)   | 45.5 (6.8) (30.1–54.1)   |
| VO <sub>2</sub> (% predicted)         | 75.2 (14.1) (46.0–106.0) |
| Peak work (W)                         | 132 (42) (65–230)        |
| % VO <sub>2</sub> peak at AT          | 60.7 (11.6) (22.0–84.0)  |
| VE <sub>peak</sub> (L/min)            | 68.9 (25.4) (24.4–130.7) |
| VE/VCO <sub>2</sub> slope             | 33.1 (4.5) (23.7–49.2)   |
| Max heart rate (bpm)                  | 170 (20) (100–196)       |
| Resting RER                           | 0.86 (0.06) (0.76–0.99)  |
| Max RER                               | 1.29 (0.14) (1.04–1.60)  |

BMI = body mass index, FEV<sub>1</sub> = forced expiratory volume in one second, CRP = C-reactive protein, AT = anaerobic threshold, VE<sub>peak</sub> = peak pulmonary ventilation, RER = respiratory exchange ratio. Data are mean (SD) (range).

## Protocoles d'entraînement

Pre- to post-exercise changes in spirometric indices, diffusion capacity, exhaled nitric oxide, and impulse oscillometry (IOS) parameters.

| Variable   | Pre               | Post                |
|--|-------------------|---------------------|
| FVC (L)  | 3.44 (3.01–3.86)  | 3.52 (3.08–3.96) *  |
| FEV <sub>1</sub> (L/min)   | 2.64 (2.29–2.99)  | 2.69 (2.33–3.06) *  |
| FEF <sub>25–75</sub> (L/min)   | 2.37 (1.92–2.84)  | 2.48 (1.99–2.98) *  |
| FEV <sub>1</sub> /FVC (%)  | 75.8 (72.6–79.1)  | 76.0 (72.7–79.3)    |
| FRC (L)  | 1.69 (1.46–1.92)  | 1.71 (1.45–1.96)    |
| MVV (L/min)  | 90.9 (77.7–104.0) | 93.1 (79.3–106.8) * |
| DL <sub>CO</sub> <sup>SB</sup> (mL CO min <sup>-1</sup> Torr <sup>-1</sup> ) | 22.9 (20.5–25.3)  | 22.8 (20.5–25.1)    |
| DL <sub>CO</sub> <sup>SB</sup> (% predicted)                                 | 92.5 (85.4–99.6)  | 92.1 (85.6–98.6)    |
| FeNO (ppb)   | 13.6 (9.0–18.2)   | 12.0 (7.9–16.2)     |



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Protocoles d'entraînement

### Interval training de haute intensité

- Intérêt pour les patients instables et/ou déconditionnés
  - Pauses

Table 1. Summary of protocols in studies from our laboratory that directly compared 6 weeks of either high-intensity interval training (HIT) or traditional endurance training

| Variable                        | HIT group  | Endurance group                         |
|---------------------------------|--|---|
| Protocol                        | 30 s × 4–6 repeats, 4.5 min rest (3 sessions per week) | 40–60 min cycling (5 sessions per week) |
| Training intensity (workload)   | 'All out' maximal effort (~500 W)                      | 65% of $\dot{V}O_{2peak}$ (~150 W)      |
| Weekly training time commitment | ~10 min (~1.5 h including rest)                        | ~4.5 h                                  |
| Weekly training volume          | ~225 kJ  | ~2250 kJ                                |

From Burgomaster *et al.* (2008).  $\dot{V}O_{2peak}$ , peak oxygen uptake.




Figure 1. Peak oxygen uptake (top panel) and the maximal activity of the mitochondrial enzyme citrate synthase measured in biopsy samples (bottom panel) obtained before (PRE) and after (POST) 6 weeks of Wingate-based high-intensity interval training (HIT) or traditional moderate-intensity endurance training (ET). Total exercise volume was 90% lower in the HIT group. Redrawn from Burgomaster *et al.* (2008) with permission. \* $P \leq 0.05$  vs Pre; main effect for time.



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org




## Protocoles d'entraînement Interval training de haute intensité

TABLE 1 Training intervention

| Week | Low intensity (%MSEC) | Duration (sec) | High intensity (%MSEC) | Duration (sec) | Intervals (number) | Supplemental O <sub>2</sub> (L/min) |
|------|-----------------------|----------------|------------------------|----------------|--------------------|-------------------------------------|
| 1    | 30                    | 60             | 50                     | 30             | 10                 | 3                                   |
| 2    | 30                    | 60             | 60                     | 30             | 12                 | 3                                   |
| 3    | 30                    | 60             | 70                     | 30             | 14                 | 3                                   |
| 4    | 30                    | 60             | 80                     | 30             | 16                 | 3                                   |
| 5    | 30                    | 60             | 90                     | 30             | 18                 | 3                                   |
| 6    | 30                    | 60             | 90                     | 30             | 20                 | 3                                   |

« PMA<sub>n</sub> » = 225W





**LYON**  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS


**3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE**

vaincrelamuco.org

federation-crcm.org



## Protocoles d'entraînement Interval training de haute intensité



[J Cyst Fibros.](#) 2014 Jan;13(1):86-91. Interval exercise training in cystic fibrosis -- effects on exercise capacity in severely affected adults. [Gruber W](#), [Orenstein DM](#), [Braumann KM](#), [Beneke R](#).





LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS


3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Protocoles d'entraînement Interval training de haute intensité



[J Physiother.](#) 2011;57(1):35-40. Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised cross-over trial. [Kuys SS<sup>1</sup>](#), [Hall K](#), [Peasey M](#), [Wood M](#), [Cobb R](#), [Bell SC](#).

[J Cyst Fibros.](#) 2013 Dec;12(6):604-8. Epub 2013 Jun 7. Xbox Kinect™ represents high intensity exercise for adults with cystic fibrosis. [Holmes H<sup>1</sup>](#), [Wood J](#), [Jenkins S](#), [Winship P](#), [Lunt D](#), [Bostock S](#), [Hill K](#).



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

[vaincrelamuco.org](http://vaincrelamuco.org)

[federation-crcm.org](http://federation-crcm.org)



## Surveillance-Précautions

- Evaluation de la dyspnée et fatigue musculaire à l'effort (Echelle de Borg)
  - Contrôle de la FC et de la saturation
  - Traitement médical si besoin (bronchodilatateurs)
  
  - Possibilité de pratiquer une activité physique en situation d'exacerbation et/ou avec oxygène
-



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les précautions

- Chambre à cathéter implantable
  - Éviter les sports de contact
  - Activités aquatiques autorisées
    - Sauf en cas de complications (infection, thrombose)





LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les précautions

- GPE
  - La plupart des sports autorisés
  - Éviter les sports avec risque de contacts violents
  - Dans certains cas, possibilité de sac à dos avec pompe portative et poche





LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les troubles sphinctériens

- Incontinence urinaire d'effort
  - ✓ 14.9% des « sportives » de loisir (Salvatore 2008)
    - *Sous estimation probable*
  - ✓ Sport de haut niveau :  $\approx$  28 à 80%\*
  - ✓ Sports à risque
    - À impact élevé : trampoline, gymnastique
  - ✓ 84% des athlètes n'en parlent pas\*\*
    - Ni à leur entraîneur, ni aux professionnels de santé
  - ✓ Facteurs déclenchants
    - Rires, saut, CAP, toux, travail abdominaux...
  - ✓ IUE révélée voire aggravée par le sport

\*Bo K, Hilde G, Staer-Jensen J, et al. Does general exercise training before and during pregnancy influence the pelvic floor "opening" and delivery outcome? A 3D/4D ultrasound study following nulliparous pregnant women from mid-pregnancy to childbirth. Br J Sports Med 2015;49:196–9.

\*\*Caylet N, Fabbro-Peray P, Mares P, et al. Prevalence and occurrence of stress urinary incontinence in elite women athletes. Can J Urol 2006;13:3174–9.




LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les contraintes ambiantes

- Altitude




Fig. 2. Altitude dependence of oxygen saturation (saO<sub>2</sub>). Given are values of all subjects at ground level (120 m a.s.l.;  $n=10$ ), in the hypobaric chamber (2000 and 3000 m;  $n=10$ ) and during the two flights (1700 and 1855 m;  $n=8$  and  $n=10$ , respectively).



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Les contraintes ambiantes

### Altitude et exercice

**TABLE 2— Arterial Oxygen Saturation at Peak Exercise and Disease Severity**

| Disease severity group <sup>1</sup> | Number of patients who desaturate to<br>< 90% and < 85% |          | Number of patients who desaturate<br>≥ 5% and ≥ 10% from baseline |          |
|-------------------------------------|---|----------|---|----------|
|                                     | < 90% <sup>2</sup>                                      | < 85%    | ≥ 5% <sup>3</sup>   | ≥ 10%    |
| Total                               | 29 of 50  | 14 of 50 | 28 of 50  | 12 of 50 |
| Normal                              | 0 of 4  | 0 of 4   | 0 of 4  | 0 of 4   |
| Mild                                | 2 of 6  | 1 of 6   | 3 of 6  | 1 of 6   |
| Moderate                            | 15 of 26  | 6 of 26  | 14 of 26  | 3 of 26  |
| Severe                              | 12 of 14  | 7 of 14  | 11 of 14  | 8 of 14  |

<sup>1</sup>Normal, FEV<sub>1</sub> > 90% predicted; mild, ≤ 70% FEV<sub>1</sub> < 90% predicted; moderate, 40% ≤ FEV<sub>1</sub> < 70% predicted; severe, FEV<sub>1</sub> < 40% predicted.

<sup>2</sup>Includes all subjects who desaturated below 90%.

<sup>3</sup>Includes all subjects who desaturated 5% or more.



**LYON**  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

**3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE**

vaincrelamuco.org

federation-crcm.org





## Cas clinique

### EFR

Jeune fille de 12 ans, atteinte de mucoviscidose dans une forme classique, associant insuffisance pancréatique externe et bronchopathie chronique, avec dilatation des bronches étendue.

|               | pré   | Théo  | LIN   | LSN   | %Théo |
|---------------|-------|-------|-------|-------|-------|
| <b>CVF</b>    | 1.41  | 2.03  | 1.61  | 2.46  | 69.5  |
| <b>VEMS</b>   | 0.96  | 1.75  | 1.36  | 2.14  | 54.8  |
| <b>VEM%VE</b> | 67.84 | 84.97 | 75.89 | 94.05 | 79.8  |
| <b>DEP</b>    | 2.81  | 4.22  | 2.80  | 5.63  | 66.5  |
| <b>DEM 75</b> | 1.94  | 3.80  | 2.54  | 5.05  | 51.1  |
| <b>DEM 50</b> | 0.72  | 2.68  | 1.82  | 3.54  | 26.8  |
| <b>DEM 25</b> | 0.24  | 1.37  | 0.81  | 1.94  | 17.5  |
| <b>DEMM</b>   | 0.53  | 2.33  | 1.51  | 3.15  | 22.6  |







LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS


3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE

vaincrelamuco.org

federation-crcm.org



## Cas clinique EFX



| Résumé                 | Repos     | AT    | Max Watts | Théo | Max 1 %théo | Recup 60 sec |
|------------------------|-----------|-------|-----------|------|-------------|--------------|
| Moyennage temporel 15s | Secondses |       |           |      |             |              |
| Temps                  | min       | 00:07 | 22:00     |      |             | 21:15        |
| t-ph                   | min       | 00:07 | 01:47     |      |             | 01:03        |
| Charge                 | W         | 0     | 0         | 72   | 0           | 0            |

| Résumé                 | Repos     | AT   | Max Watts | Théo | Max 1 %théo | Recup 60 sec |
|------------------------|-----------|------|-----------|------|-------------|--------------|
| Moyennage temporel 15s | Secondses |      |           |      |             |              |
| V'O2                   | ml/min    | 283  | 1386      | 1029 | 135         | 1252         |
| VO2/kg                 | ml/min/kg | 10.9 | 53.3      |      |             | 48.1         |
| V'CO2                  | ml/min    | 183  | 960       |      |             | 858          |

|       |   |    |     |  |  |    |
|-------|---|----|-----|--|--|----|
| VO2%m | % | 20 | 100 |  |  | 90 |
|-------|---|----|-----|--|--|----|

| Résumé                 | Repos     | AT  | Max Watts | Théo | Max 1 %théo | Recup 60 sec |
|------------------------|-----------|-----|-----------|------|-------------|--------------|
| Moyennage temporel 15s | Secondses |     |           |      |             |              |
| FC                     | l/min     | 120 | 184       | 187  | 98          | 178          |
| O2/FC                  | ml        | 2.4 | 7.5       | 6.3  | 121         | 7.0          |
| HRR %                  | %         | 36  | 2         |      |             | 5            |

| Résumé                 | Repos     | AT | Max Watts | Théo | Max 1 %théo | Recup 60 sec |
|------------------------|-----------|----|-----------|------|-------------|--------------|
| Moyennage temporel 15s | Secondses |    |           |      |             |              |
| V'E                    | L/min     | 9  | 37        | 48   | 77          | 34           |
| FR                     | l/min     | 25 | 52        | 42   | 126         | 47           |



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE



vaincrelamuco.org

federation-crcm.org



## Cas clinique

### Exercices physiques à haute intensité



Vidéo, Mme S JACQUES, Kinésithérapeute, RENNES



LYON  
5-7 AVRIL 2018  
CENTRE DES CONGRÈS

3<sup>ES</sup> JOURNÉES FRANCOPHONES  
DE LA MUCOVISCIDOSE


vaincrelamuco.org

federation-crcm.org



## Cas clinique

### Exercices physiques à haute intensité



Vidéo, Mme S JACQUES, Kinésithérapeute, RENNES

**LYON**

5-7 AVRIL 2018

CENTRE DES CONGRÈS

**3<sup>ES</sup> JOURNÉES  
FRANCOPHONES DE  
LA MUCOVISCIDOSE**



**Merci pour  
votre  
attention !**

[vaincrelamuco.org](http://vaincrelamuco.org)  
[federation-crcm.org](http://federation-crcm.org)

